SCHEMBL4693969

SCHEMBL4693969

O=C1CCCC2(CCCO2)C1

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 2/20 0.32
TRIM33 Q9UPN9 2/20 0.32
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14966409 0.94 TRIM24 (0.31) TRIM24TRIM33
SCHEMBL28272317 0.91 TRIM24 (0.32) TRIM24TRIM33ALDH1A1
SCHEMBL18366406 0.84
SCHEMBL614887 0.84
SCHEMBL1813694 0.83 TRIM24 (0.38) TRIM24TRIM33ALDH1A1
SCHEMBL12542094 0.83 ALDH1A1 (0.31) TRIM24TRIM33ALDH1A1
SCHEMBL319059 0.79
SCHEMBL134965 0.77 TRIM24 (0.35) TRIM24TRIM33ALDH1A1
SCHEMBL31570418 0.77 KCNH2 (0.32)
SCHEMBL15128955 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197424-A1 FRESHENING COMPOSITIONS AND DEVICES COMPRISING SAME THE PROCTER & GAMBLE COMPANY (US) 2017-08-02 EP claimed
WO-2016049398-A1 FRESHENING COMPOSITIONS AND DEVICES COMPRISING SAME THE PROCTER & GAMBLE COMPANY (US) 2016-03-31 WO claimed
US-11334694-B2 Personal care compositions comprising malodor reduction compositions THE PROCTER & GAMBLE COMPANY (US) 2022-05-17 US disclosed
US-11334695-B2 Antiperspirant and deodorant compositions comprising malodor reduction compositions THE PROCTER & GAMBLE COMPANY (US) 2022-05-17 US disclosed
US-10792384-B2 Rolled fibrous structures comprising encapsulated malodor reduction compositions THE PROCTER & GAMBLE COMPANY (US) 2020-10-06 US disclosed
US-10552557-B2 Freshening compositions and devices comprising same THE PROCTER & GAMBLE COMPANY (US) 2020-02-04 US disclosed
US-20190184049-A1 Rolled Fibrous Structures Comprising Encapsulated Malodor Reduction Compositions THE PROCTER & GAMBLE COMPANY 2019-06-20 US disclosed
US-20190155975-A9 Antiperspirant and Deodorant Compositions Comprising Malodor Reduction Compositions THE PROCTER & GAMBLE COMPANY 2019-05-23 US disclosed
US-10240108-B2 Particles for malodor reduction THE PROCTER & GAMBLE COMPANY (US) 2019-03-26 US disclosed
US-20190029928-A1 Fibrous Structures Comprising Malodor Reduction Compositions THE PROCTER & GAMBLE COMPANY 2019-01-31 US disclosed
US-10113140-B2 Freshening compositions and devices comprising same THE PROCTER & GAMBLE COMPANY (US) 2018-10-30 US disclosed
US-20160089464-A1 MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY 2016-03-31 US disclosed
US-20160089317-A1 ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY 2016-03-31 US disclosed
US-20160090555-A1 CLEANING AND/OR TREATMENT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY 2016-03-31 US disclosed
US-20160090557-A1 SUBSTRATES COMPRISING MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY 2016-03-31 US disclosed
WO-2013072882-A1 2 -AMINO- 1, 8 -NAPHTHYRIDINE-3 -CARBOXAMIDE DERIVATIVES AS ANTIMICROBIAL AGENTS ACTELION PHARMACEUTICALS LTD (CH) 2013-05-23 WO disclosed
EP-2585444-A1 AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS Boehringer Ingelheim International GmbH (DE) 2013-05-01 EP disclosed
WO-2011161128-A1 AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-29 WO disclosed
EP-1877364-A1 PHENYLACETYLENE DERIVATIVES HAVING MGLUR5 RECEPTOR AFFINITY Novartis AG (CH) 2008-01-16 EP disclosed
WO-2006114260-A1 PHENYLACETYLENE DERIVATIVES HAVING MGLUR5 RECEPTOR AFFINITY NOVARTIS AG (CH) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10552557-B2 Freshening compositions and devices comprising same CFD, C5, PDE6G TRIM24 3203/4885TRIM33 1936/4885ALDH1A1 1316/4885
US-20160089317-A1 ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS LPO, QDPR, TYR TRIM24 2843/4885TRIM33 1005/4885ALDH1A1 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.